TrialJournal of atherosclerosis and thrombosis2025

Pharmacokinetics and Safety of Pemafibrate in Patients with both Dyslipidemia and Severe Renal Impairment: A Phase 4 Study.

Shun Ishibashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.